DuPont de Nemours (DD) Earnings Date & Reports

DuPont delivered robust Q1 results, surpassing both consensus estimates and its own prior guidance. Net sales reached $1.681 billion, up 4% from $1.612 billion in Q1 2025, driven by 2% organic growth and 2% currency benefits; this topped analyst expectations of around $1.66-$1.677 billion. Organic growth reflected strength in healthcare technologies and aerospace, offset by construction weakness and logistics issues.

Adjusted earnings per share (EPS) hit $0.55, up 53% year-over-year from $0.36 and exceeding forecasts of $0.48-$0.50, aided by higher segment earnings, productivity, lower share count, and a favorable tax rate. GAAP EPS from continuing operations was $0.36, up 89%.

Operating EBITDA climbed 15% to $414 million (margin 24.6%, +230 bps), beating company guidance of ~$395 million, thanks to organic sales, favorable product mix, and productivity savings. Key metrics included cash from operations at $232 million (up 201%) and transaction-adjusted free cash flow (FCF) of $147 million (65% conversion).

Segments shone: Healthcare & Water Technologies net sales up 6% to $806 million (organic +3%), EBITDA +9% to $244 million (margin +110 bps to 30.3%); Diversified Industrials sales +3% to $875 million (organic flat), EBITDA +8% to $200 million (margin +110 bps to 22.9%).

Guidance was raised: Q2 net sales ~$1.8 billion (organic ~3%), operating EBITDA ~$430 million, adjusted EPS ~$0.59; full-year net sales $7.155-$7.215 billion (~4% organic), operating EBITDA $1.730-$1.760 billion, adjusted EPS $2.35-$2.40 (up $0.10 from prior $2.25-$2.30).

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis of stocks like DD.

Market Reaction and Investor Sentiment

DuPont's shares rallied sharply post-earnings, climbing over 10% to around $50 in early trading on May 5, reflecting enthusiasm for the earnings beat, margin expansion, and raised full-year outlook. Investors interpreted the results as evidence of operational strength and strategic progress, particularly the Aramids divestiture proceeds funding capital returns via a $275 million ASR. Sentiment turned bullish, with focus shifting to sustained organic growth and pricing discipline amid input cost pressures.

Forward Outlook and Key Factors to Monitor

DuPont's raised full-year guidance underscores confidence in a strong 2026, projecting ~4% organic sales growth, including 1% from pricing to counter higher input costs tied to Middle East tensions. Operating EBITDA midpoint rises to ~$1.745 billion, supported by productivity and mix improvements, while adjusted EPS guidance of $2.35-$2.40 incorporates Aramids interest income and a 24-25% tax rate.

Segment trajectories merit attention: Healthcare & Water Technologies eyes mid-single-digit organic growth on medical packaging, biopharma, and industrial water demand; Diversified Industrials anticipates low-single-digit gains from aerospace and automotive recovery, despite lingering construction softness. Q2 guidance signals momentum with ~3% organic sales growth.

Key monitors include execution on pricing amid inflation, free cash flow conversion (targeting strong generation for buybacks/dividends), and impacts from the Aramids sale integration. Broader chemical sector dynamics, currency fluctuations (now less than 1% tailwind), and geopolitical risks will shape performance. Upcoming catalysts: Q2 results in August and progress on portfolio optimization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations